AvengeBio was a biotechnology company that is now permanently closed.

AvengeBio

Adarx is a technology company that specializes in developing advanced data analytics and artificial intelligence solutions for healthcare and life sciences. Their platform aims to accelerate drug discovery and development by providing insights through data integration, machine learning, and predictive modeling.

Zhen Li

Adarx

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

George Rathmann

Amgen Inc.

Candid Therapeutics focuses on revolutionizing treatment paradigms for autoimmune diseases.

Metric
Company Name	AvengeBio	Adarx	Amgen Inc.	Candid Therapeutics
Symbol			AMGN
MSH ID	COM:AVENGEBIO	COM:ADARX	COM:AMGEN	COM:CANDIDRX
Market	PRIVATE	PRIVATE	STOCKS	PRIVATE
Sector	Healthcare & Health Services	Technology	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Healthcare Technology	Drug Manufacturers - General	Biotechnology
Country	US	US	US	US
Stage				Series A
Employee Count	11	53	26.70K
Website	avengebio.com	adarx.com	amgen.com	candidrx.com
LinkedIn		adarx-pharmaceuticals-inc	amgen
Founders

Metric
Market Cap	1.20B	172.56B
Enterprise Value
Monthly Web Traffic		1.00M	281
Web Traffic Growth		-0.02	-0.84
Valuation
Raised Capital		28.50B	370M

Metric
Revenue			28.19B
Revenue (LTM)
Revenue (NTM)
Gross Profit			19.74B
EBITDA			7.90B
Operating Income			7.90B
Net Income			6.72B
EPS			12.56
Diluted EPS			12.49
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin			0.70
Operating Profit Margin			0.32
EBITDA Margin			0.28
Net Profit Margin			0.24
Return on Equity			1.03
Return on Assets			0.07
Return on Capital Employed			0.12

AVEN

COM:AVENGEBIO

AvengeBio

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio			22.81
P/B Ratio			22.55
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio			6.11
EV Multiple			12.57

Metric
Days Sales Outstanding			83.59
Days Payables Outstanding			69.95
Days Inventory Outstanding			411.08
Operating Cycle			513.92
Cash Conversion Cycle			445.24
Asset Turnover			0.34

Metric
Operating Cash Flow			8.47B
Free Cash Flow			7.36B
Cash Flow to Debt			0.13
Operating Cash Flow/Sales			0.30
Free Cash Flow Yield			0.06

Metric
Cash & Equivalents			10.94B
Accounts Receivable			-1.01B
Inventory			9.52B
Goodwill			18.63B
Debt to Capitalization			0.93
Debt to Assets			0.67
Current Ratio			2.86
Quick Ratio			1.62

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue			0.03
R&D to Revenue			0.17
SG&A to Revenue